• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients with Rheumatoid Arthritis in Remission While Receiving Etanercept Plus Methotrexate Therapy May Require Adjustment of Dosing Regimen When Switched to Methotrexate Monotherapy.

作者信息

Bannwarth Bernard

出版信息

J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.160815.

DOI:10.3899/jrheum.160815
PMID:28148757
Abstract
摘要

相似文献

1
Patients with Rheumatoid Arthritis in Remission While Receiving Etanercept Plus Methotrexate Therapy May Require Adjustment of Dosing Regimen When Switched to Methotrexate Monotherapy.接受依那西普联合甲氨蝶呤治疗病情缓解的类风湿关节炎患者在转换为甲氨蝶呤单药治疗时可能需要调整给药方案。
J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.160815.
2
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.类风湿关节炎患者使用依那西普与甲氨蝶呤联合治疗后疾病缓解及影像学进展持续停止
Arthritis Rheum. 2007 Dec;56(12):3928-39. doi: 10.1002/art.23141.
3
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.依那西普联合甲氨蝶呤治疗中重度类风湿关节炎患者的依那西普维持、减量或停药（PRESERVE）：一项随机对照试验。
Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17.
4
Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy.联用依那西普和甲氨蝶呤对既往接受单药治疗的中度活动性类风湿关节炎患者影像学进展的抑制作用。
Ann Rheum Dis. 2009 Jul;68(7):1113-8. doi: 10.1136/ard.2008.094375. Epub 2008 Aug 21.
5
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.一项针对正在接受甲氨蝶呤治疗的类风湿关节炎患者使用重组肿瘤坏死因子受体：Fc融合蛋白依那西普的试验。
N Engl J Med. 1999 Jan 28;340(4):253-9. doi: 10.1056/NEJM199901283400401.
6
Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.在生物制剂可及性有限的地区开展的国际达标治疗研究：依那西普联合 DMARD 治疗与单独 DMARD 治疗在活动性类风湿关节炎中维持缓解的比较。
Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9.
7
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.依那西普与甲氨蝶呤单药及联合用药治疗类风湿关节炎的比较：TEMPO研究的两年临床和影像学结果，一项双盲随机试验
Arthritis Rheum. 2006 Apr;54(4):1063-74. doi: 10.1002/art.21655.
8
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.与单药治疗相比，依那西普与甲氨蝶呤联合治疗类风湿关节炎患者的疗效：双盲随机对照试验
Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7.
9
Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.类风湿关节炎患者同时使用甲氨蝶呤时依那西普的药代动力学未改变。
J Clin Pharmacol. 2004 Nov;44(11):1235-43. doi: 10.1177/0091270004268049.
10
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.托珠单抗、甲氨蝶呤或二者联合治疗早期类风湿关节炎（U-Act-Early）：一项多中心、随机、双盲、双模拟、策略试验。
Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7.

引用本文的文献

1
Long-term evaluation of rheumatoid arthritis activity with erythrocyte methotrexate-polyglutamate 3.用红细胞甲氨蝶呤-多聚谷氨酸3对类风湿关节炎活动度进行长期评估
Fundam Clin Pharmacol. 2025 Feb;39(1):e13050. doi: 10.1111/fcp.13050.